Stocks
Clene Inc.CLNN
NASDAQHealthcareBiotechnology$3.88
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing therapies for neurological disorders, with a focus on amyotrophic lateral sclerosis (ALS) and multiple sclerosis. Its lead program targets misfolded protein accumulation in motor neurons, a mechanism distinct from most competitors. Investors track CLNN for its orphan drug designations and upcoming Phase 2/3 trial readouts.
52W Range: $3.02-$13.50
Congressional Interest in Clene Inc. (CLNN)
No congressional trades have been disclosed for Clene Inc. (CLNN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CLNN?
No congressional trades found for this stock.